SNA
50
-2
TRIP
47
-5
LB
37
2
MPC
60
-3
ETN
61
5
PBI
49
-6
LEN
33
-3
XRAY
31
-6
ABT
39
-3
LLY
70
2
MU
82
4
BA
58
8
FRT
56
3
V
38
2
F
56
-2
LOW
50
-2
EXR
59
4
DVA
31
-3
ADSK
49
2
GT
34
-4
SNA
50
-2
TRIP
47
-5
LB
37
2
MPC
60
-3
ETN
61
5
PBI
49
-6
LEN
33
-3
XRAY
31
-6
ABT
39
-3
LLY
70
2
MU
82
4
BA
58
8
FRT
56
3
V
38
2
F
56
-2
LOW
50
-2
EXR
59
4
DVA
31
-3
ADSK
49
2
GT
34
-4
Financhill
Back

Nektar Therapeutics Stock Predictions

Meet America's Newest $1B Unicorn

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Sell
37

NKTR
Nektar Therapeutics

Last Price:
$37.60
Seasonality Move:
-2.36%

7 Day Trial

ALL ACCESS PASS

$ 7

Exxon and Chevron Have an Unlikely New Competitor

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at

Nektar Therapeutics Stock Forecast

  • Over the next 52 weeks, Nektar Therapeutics has on average historically risen by 23.9% based on the past 31 years of stock performance.
  • Nektar Therapeutics has risen higher in 16 of those 31 years over the subsequent 52-week period, corresponding to a historical accuracy of 51.61%
  • Is Nektar Therapeutics Stock Undervalued?
    The current Nektar Therapeutics [NKTR] share price is $37.68. The Score for NKTR is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.
  • NKTR is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Nektar Therapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, Nektar Therapeutics has on average historically risen by 23.9% based on the past 31 years of stock performance.

Nektar Therapeutics Stock Rating

Sell
37
Nektar Therapeutics (NKTR) is a Sell

Is Nektar Therapeutics overpriced?

  • Nektar Therapeutics has risen higher in 16 of those 31 years over the subsequent 52-week period, corresponding to a historical accuracy of 51.61%

Nektar Therapeutics Stock Price History

Is NKTR stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and NKTR is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
nektar.com

52-Week Data

52-Week High:
66.92
52-Week Low:
6.48

Prediction Charts

Market Cap:
651.9M
Price in USD:
37.68
Volume:
674K
Beta:
1.26

Technical Analysis

SMA50:
51.02
SMA100:
51.66
SMA200:
33.96
52-Wk Change:
181.71%

Stock Predictions

  • Is Nektar Therapeutics stock public?
    Yes, Nektar Therapeutics is a publicly traded company.
  • What is the Nektar Therapeutics stock quote today?
    The Nektar Therapeutics stock price is 37.68 USD today.
  • How to buy Nektar Therapeutics stock online?
    You can buy Nektar Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-26 43.61 44.49 44.91 43.01
Dec-29 44.01 42.73 44.40 42.25
Dec-30 42.47 41.90 42.61 41.32
Dec-31 41.90 42.28 42.46 41.55
Jan-5 43.77 44.47 44.48 43.00
Jan-6 44.49 42.97 45.34 42.69
Jan-7 42.94 43.51 44.98 42.58
Jan-8 43.51 41.44 43.79 41.25
Jan-9 41.20 39.71 41.89 39.61
Jan-12 39.71 38.77 39.71 37.35
Jan-13 38.70 36.58 38.70 35.74
Jan-14 35.95 36.09 37.69 35.70
Jan-15 36.16 35.36 36.39 34.34
Jan-16 35.40 37.68 38.29 35.40

Nektar Therapeutics Earnings

Nektar Therapeutics Earnings Report: Per Share Nektar Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

Nektar Therapeutics Forecast Revenue Growth

Nektar Therapeutics Stock Analysis: Historical quarterly revenues per share for Nektar Therapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.41 per share, a decrease next quarter of $0.00 per share, a decrease this year of $3.54 per share, and a decrease next year of $2.39 per share.

* Nektar Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.